Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2019

30.07.2019 | Epidemiology

Risk of breast cancer among women with benign ovarian tumors: a Danish nationwide cohort study

verfasst von: Mathilde Gottschau, Allan Jensen, Kristian Reinholdt, Sonia Guleria, Christian Munk, Lene Mellemkjær, Susanne K. Kjær

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the association between benign ovarian tumors and subsequent risk of breast cancer, and to examine this association according to type of benign ovarian tumors.

Methods

This nationwide cohort study comprised all Danish women diagnosed with a benign ovarian tumor during 1978–2016 (n = 158,221) identified through the Danish National Patient Register. The cohort was linked to the Danish Cancer Registry to identify all cases of breast cancer, and standardized incidence ratios (SIR) and 95% confidence intervals (CI) were calculated.

Results

Overall, women with a benign ovarian tumor were at significantly increased risk of breast cancer. The risk was confined to women with a solid ovarian tumor (SIR 1.09; 95% CI 1.05–1.13), particularly in women ≥ 50 years at benign tumor diagnosis (SIR 1.19; 95% CI 1.12–1.26). The risk remained increased up to 20 years or more after the diagnosis of a solid ovarian tumor (SIR 1.11; 95% CI 1.04–1.18), and women with a solid tumor were at increased risk of ductal, lobular, and other types of breast cancer, although most consistent for the lobular subtype. For cystic tumors, this association was confined to ductal breast cancer in women with the tumor diagnosed at age ≥ 50 years.

Conclusions

Women with a benign ovarian tumor were at increased risk of breast cancer. This association was largely confined to women with a solid ovarian tumor, and the excess risk was present 20 years or more after the ovarian tumor diagnosis. The underlying mechanism is unknown and should be investigated further.
Literatur
2.
Zurück zum Zitat Engholm G, Ferlay J, Christensen N, Hansen H L, Hertzum-Larsen R, Johannesen T B, et al NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic Countries, Version 8.1 (28.06.2018). Association of the Nordic Cancer Registries, Danish Cancer Society. http://www.ancr.nu. Accessed 12 Dec 2018 Engholm G, Ferlay J, Christensen N, Hansen H L, Hertzum-Larsen R, Johannesen T B, et al NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic Countries, Version 8.1 (28.06.2018). Association of the Nordic Cancer Registries, Danish Cancer Society. http://​www.​ancr.​nu. Accessed 12 Dec 2018
3.
Zurück zum Zitat Jensen MB, Ejlertsen B, Mouridsen HT, Christiansen P, for the Danish Breast Cancer Cooperative Group (2016) Improvements in breast cancer survival between 1995 and 2012 in Denmark: the importance of earlier diagnosis and adjuvant treatment. Acta Oncol 55(Suppl 2):24–35 Jensen MB, Ejlertsen B, Mouridsen HT, Christiansen P, for the Danish Breast Cancer Cooperative Group (2016) Improvements in breast cancer survival between 1995 and 2012 in Denmark: the importance of earlier diagnosis and adjuvant treatment. Acta Oncol 55(Suppl 2):24–35
4.
Zurück zum Zitat Anderson WF, Pfeiffer RM, Dores GM, Sherman ME (2006) Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomark Prev 15(10):1899–1905CrossRef Anderson WF, Pfeiffer RM, Dores GM, Sherman ME (2006) Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomark Prev 15(10):1899–1905CrossRef
5.
Zurück zum Zitat McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases: breast cancer—epidemiology, risk factors and genetics. BMJ 321(7261):624–628CrossRef McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases: breast cancer—epidemiology, risk factors and genetics. BMJ 321(7261):624–628CrossRef
6.
Zurück zum Zitat Dossus L, Benusiglio PR (2015) Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res 17:37CrossRef Dossus L, Benusiglio PR (2015) Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res 17:37CrossRef
7.
Zurück zum Zitat McDonald JM, Modesitt SC (2006) The incidental postmenopausal adnexal mass. Clin Obstet Gynecol 49(3):506–516CrossRef McDonald JM, Modesitt SC (2006) The incidental postmenopausal adnexal mass. Clin Obstet Gynecol 49(3):506–516CrossRef
8.
Zurück zum Zitat Booth M, Beral V, Maconochie N, Carpenter L, Scott C (1992) A case-control study of benign ovarian tumours. J Epidemiol Community Health 46:528–531CrossRef Booth M, Beral V, Maconochie N, Carpenter L, Scott C (1992) A case-control study of benign ovarian tumours. J Epidemiol Community Health 46:528–531CrossRef
9.
Zurück zum Zitat Greenlee RT, Kessel B, Williams CR, Riley TL, Ragard LR, Hartge P et al (2010) Prevalence, incidence and natural history of simple ovarian cysts among women over age 55 in a large cancer screening trial. Am J Obstet Gynecol 202(4):373CrossRef Greenlee RT, Kessel B, Williams CR, Riley TL, Ragard LR, Hartge P et al (2010) Prevalence, incidence and natural history of simple ovarian cysts among women over age 55 in a large cancer screening trial. Am J Obstet Gynecol 202(4):373CrossRef
10.
Zurück zum Zitat Christensen JT, Boldsen JL, Westergaard JG (2002) Functional ovarian cysts in premenopausal and gynecologically healthy women. Contraception 66(3):153–157CrossRef Christensen JT, Boldsen JL, Westergaard JG (2002) Functional ovarian cysts in premenopausal and gynecologically healthy women. Contraception 66(3):153–157CrossRef
11.
Zurück zum Zitat Parazzini F, Moroni S, Negri E, Crosignani PG (1996) Risk factors for seromucinous benign ovarian cysts in northern Italy. J Epidemiol Community Health 51:449–452CrossRef Parazzini F, Moroni S, Negri E, Crosignani PG (1996) Risk factors for seromucinous benign ovarian cysts in northern Italy. J Epidemiol Community Health 51:449–452CrossRef
12.
Zurück zum Zitat Parazzini F, Moroni S, Negri E, La Vecchia C, Dal Pino D, Ricci E (1996) Risk factors for functional ovarian cysts. Epidemiology 7(5):547–549CrossRef Parazzini F, Moroni S, Negri E, La Vecchia C, Dal Pino D, Ricci E (1996) Risk factors for functional ovarian cysts. Epidemiology 7(5):547–549CrossRef
13.
Zurück zum Zitat Sharma A, Gentry-Maharaj A, Burnell M, Fourkala E, Campbell S, Amso N et al (2012) Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK collaborative trial of ovarian cancer screening (UKCTOCS): a prospective cohort study. BJOG 119(2):207–219CrossRef Sharma A, Gentry-Maharaj A, Burnell M, Fourkala E, Campbell S, Amso N et al (2012) Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK collaborative trial of ovarian cancer screening (UKCTOCS): a prospective cohort study. BJOG 119(2):207–219CrossRef
14.
Zurück zum Zitat Borgfeldt C, Andolf E (2004) Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand 83:395–400CrossRef Borgfeldt C, Andolf E (2004) Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand 83:395–400CrossRef
15.
Zurück zum Zitat Franceschi S, La Vecchia C, Negri E, Parazzini F, Boyle P (1990) Breast cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 26(7):781–785CrossRef Franceschi S, La Vecchia C, Negri E, Parazzini F, Boyle P (1990) Breast cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 26(7):781–785CrossRef
16.
Zurück zum Zitat Schairer C, Persson I, Falkeborn M, Naessen T, Troisi R, Brinton LA (1997) Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer 70:150–154CrossRef Schairer C, Persson I, Falkeborn M, Naessen T, Troisi R, Brinton LA (1997) Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer 70:150–154CrossRef
17.
Zurück zum Zitat Moseson M, Koenig KL, Shore RE, Pasternack BS (1993) The influence of medical conditions associated with hormones on the risk of breast cancer. Int J Epidemiol 22(6):1000–1009CrossRef Moseson M, Koenig KL, Shore RE, Pasternack BS (1993) The influence of medical conditions associated with hormones on the risk of breast cancer. Int J Epidemiol 22(6):1000–1009CrossRef
18.
Zurück zum Zitat Knight JA, Lesosky M, Blackmore KM, Voigt LF, Holt VL, Bernstein L et al (2008) Ovarian cysts and breast cancer: results from the Women’s Contraceptive and Reproductive Experiences Study. Breast Cancer Res Treat 109(1):157–164CrossRef Knight JA, Lesosky M, Blackmore KM, Voigt LF, Holt VL, Bernstein L et al (2008) Ovarian cysts and breast cancer: results from the Women’s Contraceptive and Reproductive Experiences Study. Breast Cancer Res Treat 109(1):157–164CrossRef
19.
Zurück zum Zitat Knight JA, John EM, Milne RL, Dite GS, Balbuena R, Shi EJ et al (2006) An inverse association between ovarian cysts and breast cancer in the Breast Cancer Family Registry. Int J Cancer 118(1):197–202CrossRef Knight JA, John EM, Milne RL, Dite GS, Balbuena R, Shi EJ et al (2006) An inverse association between ovarian cysts and breast cancer in the Breast Cancer Family Registry. Int J Cancer 118(1):197–202CrossRef
20.
Zurück zum Zitat Bosetti C, Scotti L, Negri E, Talamini R, Levi F, Franceschi S et al (2006) Benign ovarian cysts and breast cancer risk. Int J Cancer 119(7):1679–1682CrossRef Bosetti C, Scotti L, Negri E, Talamini R, Levi F, Franceschi S et al (2006) Benign ovarian cysts and breast cancer risk. Int J Cancer 119(7):1679–1682CrossRef
21.
Zurück zum Zitat Talamini R, Franceschi S, Favero A, Negri E, La Vecchia C (1997) Selected medical conditions and risk of breast cancer. Br J Cancer 75(11):1699–1703CrossRef Talamini R, Franceschi S, Favero A, Negri E, La Vecchia C (1997) Selected medical conditions and risk of breast cancer. Br J Cancer 75(11):1699–1703CrossRef
22.
Zurück zum Zitat Jung SJ, Song M, Choi JY, Song N, Park SK, Yoo KY et al (2013) Association of selected medical conditions with breast cancer risk in Korea. J Prev Med Public Health 46(6):346–352CrossRef Jung SJ, Song M, Choi JY, Song N, Park SK, Yoo KY et al (2013) Association of selected medical conditions with breast cancer risk in Korea. J Prev Med Public Health 46(6):346–352CrossRef
23.
Zurück zum Zitat Weiss HA, Brinton LA, Potischman NA, Brogan D, Coates RJ, Gammon MD et al (1999) Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol 28:816–823CrossRef Weiss HA, Brinton LA, Potischman NA, Brogan D, Coates RJ, Gammon MD et al (1999) Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol 28:816–823CrossRef
24.
Zurück zum Zitat Lynge E, Sandegaard JL, Rebolj M (2011) The Danish national patient register. Scand J Public Health 39(7 Suppl):30–33CrossRef Lynge E, Sandegaard JL, Rebolj M (2011) The Danish national patient register. Scand J Public Health 39(7 Suppl):30–33CrossRef
25.
Zurück zum Zitat Pedersen CB (2011) The Danish civil registration system. Scand J Public Health 39(7 Suppl):22–25CrossRef Pedersen CB (2011) The Danish civil registration system. Scand J Public Health 39(7 Suppl):22–25CrossRef
26.
Zurück zum Zitat Gjerstorff ML (2011) The Danish cancer registry. Scand J Public Health 39(7 Suppl):42–45CrossRef Gjerstorff ML (2011) The Danish cancer registry. Scand J Public Health 39(7 Suppl):42–45CrossRef
27.
Zurück zum Zitat Ressing M, Blettner M, Klug SJ (2010) Data analysis of epidemiological studies: part 11 of a series on evaluation of scientific publications. Dtsch Arztebl Int 107(11):187–192PubMedPubMedCentral Ressing M, Blettner M, Klug SJ (2010) Data analysis of epidemiological studies: part 11 of a series on evaluation of scientific publications. Dtsch Arztebl Int 107(11):187–192PubMedPubMedCentral
28.
Zurück zum Zitat Breslow NE, Day NE (1987) Rates and rate standardization. Statistical methods in cancer research—volume II: the design and analysis of cohort studies. IARC Scientific Publications No 82. International Agency for Research on Cancer, pp 48–79 Breslow NE, Day NE (1987) Rates and rate standardization. Statistical methods in cancer research—volume II: the design and analysis of cohort studies. IARC Scientific Publications No 82. International Agency for Research on Cancer, pp 48–79
29.
Zurück zum Zitat Soegaard M, Kjaer SK, Cox M, Wozniak E, Hogdall E, Hogdall C et al (2008) BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res 14(12):3761–3767CrossRef Soegaard M, Kjaer SK, Cox M, Wozniak E, Hogdall E, Hogdall C et al (2008) BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res 14(12):3761–3767CrossRef
30.
Zurück zum Zitat Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A (2001) Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 93(16):1215–1223CrossRef Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A (2001) Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 93(16):1215–1223CrossRef
31.
Zurück zum Zitat Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352:1223–1236CrossRef Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352:1223–1236CrossRef
32.
Zurück zum Zitat Barry JA, Azizia MM, Hardiman PJ (2014) Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 20(5):748–758CrossRef Barry JA, Azizia MM, Hardiman PJ (2014) Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 20(5):748–758CrossRef
33.
Zurück zum Zitat Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L (2015) Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol 136(1):99–103CrossRef Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L (2015) Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol 136(1):99–103CrossRef
34.
Zurück zum Zitat Metindir J, Aslan S, Bilir G (2005) Ovarian cyst formation in patients using tamoxifen for breast cancer. Jpn J Clin Oncol 35(10):607–611CrossRef Metindir J, Aslan S, Bilir G (2005) Ovarian cyst formation in patients using tamoxifen for breast cancer. Jpn J Clin Oncol 35(10):607–611CrossRef
35.
Zurück zum Zitat Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4):276–285CrossRef Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4):276–285CrossRef
Metadaten
Titel
Risk of breast cancer among women with benign ovarian tumors: a Danish nationwide cohort study
verfasst von
Mathilde Gottschau
Allan Jensen
Kristian Reinholdt
Sonia Guleria
Christian Munk
Lene Mellemkjær
Susanne K. Kjær
Publikationsdatum
30.07.2019
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05369-8

Weitere Artikel der Ausgabe 1/2019

Breast Cancer Research and Treatment 1/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.